Lv51
1310 积分 2024-02-01 加入
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
5个月前
已完结
Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT
5个月前
已完结
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
5个月前
已完结
370P A phase Ib study to evaluate the efficacy and safety of afuresertib plus fulvestrant in subjects with locally advanced or metastatic HR+/HER2- breast cancer who failed standard of care therapies: A subgroup analysis of efficacy in PIK3CA/AKT1/PTEN-altered subjects
5个月前
已完结
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044)
5个月前
已完结
A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma
5个月前
已完结
Evaluating everolimus for the treatment of breast cancer
5个月前
已完结
皖公网安备34019202002308
